Summary
The Economic National Supply (WL) is expanding the reporting and storage obligations for vital pharmaceutical active ingredients as of January 15, 2026. Eight additional active ingredients are now subject to reporting requirements, including intensive care medications and systemic glucocorticoids. Five further active ingredients are being placed under storage obligations. The measures are intended to strengthen supply security in the Swiss healthcare system and prevent shortages of critical medications.
People & Institutions
- Economic National Supply (WL)
- Federal Council (regulatory authority)
Topics
- Pharmaceutical supply security
- Reporting obligation for vital active ingredients
- Mandatory storage requirements
- Digital pharmaceutical platform
- Intensive care medicine
- Systemic glucocorticoids
Detailed Summary
The WL pharmaceutical division conducts a comprehensive review of regulations every two years, which govern the reporting and storage obligations for vital pharmaceutical active ingredients. With the current review, eight additional active ingredients are now subject to reporting requirements. These focus on intensive care medications as well as representatives of the systemic glucocorticoids active ingredient group (cortisone agents for anti-inflammatory purposes). The reporting obligation annex will henceforth comprise approximately 330 active ingredients.
Manufacturers and distributors of medications with reportable active ingredients must notify the WL reporting office of supply shortages and delivery interruptions. They must specify how long the disruption is expected to last and whether equivalent alternatives are available. Since mid-2025, this communication has been conducted via the digital pharmaceutical platform, which informs all stakeholders about the current supply situation.
In parallel, five active ingredients are being newly placed under storage obligations, including medications for blood pressure reduction and sedatives. The mandatory storage reserves will thus comprise approximately 120 active ingredients and serve as a supply buffer when the market can no longer independently ensure supply. These reserves cover average demand for two to three months.
The evaluation of active ingredients is conducted based on medical necessity, supply chain stability, and supply risk. The recommendations are discussed in a broadly supported consultation with cantons, health organizations, and pharmaceutical companies. The consultation in summer 2025 welcomed the expansion in principle.
Key Statements
- Eight new active ingredients are subject to reporting requirements as of January 15, 2026, focused on intensive care medicine and anti-inflammatory agents
- Five active ingredients are newly placed under storage obligations, particularly for blood pressure reduction and sedatives
- Reporting obligation annex now comprises ~330 active ingredients, storage obligation annex ~120 active ingredients
- Digital pharmaceutical platform operational since mid-2025 for supply reporting
- Mandatory reserves cover 2–3 months of average demand
Stakeholders & Affected Parties
| Stakeholder | Impact |
|---|---|
| Hospitals & Intensive Care Units | Benefit from improved supply security for critical medications |
| Pharmaceutical Companies | New reporting and storage obligations, increased administrative burden |
| Cantons & Health Authorities | Better overview of supply shortages through digital platform |
| Patients | Reduced risk of supply failures for vital medications |
| Pharmacies & Wholesale | New storage obligations for 5 additional active ingredients |
Opportunities & Risks
| Opportunities | Risks |
|---|---|
| Stronger supply security for critical medications | Increased storage costs for pharmaceutical industry |
| Early warning of shortages through reporting obligation | Administrative burden for manufacturers and distributors |
| Better coordination through digital platform | Insufficient financing mechanisms for mandatory reserves |
| Focus on intensive care improves emergency care | Possible transition difficulties during implementation |
Action Relevance
Relevant for decision-makers:
- Pharmaceutical companies should adapt their reporting processes to meet expanded requirements by January 15, 2026
- Storage companies must establish storage obligations for the 5 new active ingredients
- Cantons and health authorities should actively use the digital pharmaceutical platform and conduct training
- Financing questions for mandatory reserves remain unresolved and require further working group projects
- Note: Further concerns from the consultation (broader expansion, financing) will be incorporated into future evaluations
Quality Assurance & Fact-Checking
- [x] Central statements and figures verified
- [x] All data from official federal press release
- [x] No unconfirmed data identified
- [x] No apparent political bias detected
Supplementary Research
Recommended sources for further reading:
- Federal Office for Economic National Supply (BWL) – Official documentation of regulatory changes and annexes
- Pharmasuisse – Industry position on storage obligations and cost implications
- Swissmedic – Regulatory framework for pharmaceutical safety in Switzerland
Sources
Primary Source:
Press Release Economic National Supply – "Improved Supply: WL Expands Reporting and Storage Obligations for Vital Pharmaceutical Active Ingredients" – https://www.news.admin.ch/de/newnsb/WcxezX0AY3h6L7mEpdjxE (January 12, 2026)
Supplementary Sources:
- Ordinance on the Reporting Office for Vital Human Pharmaceuticals (SR)
- Ordinance on Mandatory Storage of Pharmaceuticals (SR)
- Ordinance of the DEFR on Mandatory Storage of Pharmaceuticals (SR)
Verification Status: ✓ Facts verified on January 12, 2026
This text was created with the support of Claude.
Editorial responsibility: clarus.news | Fact-checking: January 12, 2026